Skip to main content

Table 1 Demographic and Clinical Characteristics at Baseline

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

Characteristics Enrolled patients
(N = 879)
Demographics Age, years 54.4 ± 11.5
  Female, no (%) 692 (78.7)
  White, no (%) 820 (93.3)
  Disease duration, years 12.5 ± 9.7
  RF > 20 IU/mL, no (%) 661 (75.2)
ACR core set Tender joint count (0-68 scale) 14.9 ± 7.1
  Swollen joint count (0-66 scale) 13.2 ± 5.2
  Patient's assessment of pain, mm (0-100 mm VAS)a 66.2 ± 22.3
  Patient's global assessment of disease activity, mm (0-100 mm VAS)b 65.1 ± 22.7
  Physician's global assessment of disease activity, mm (0-100 mm VAS)b 63.7 ± 17.6
  HAQ-DI score (0-3 scale)c 1.5 ± 0.6
  DAS28 Score 6.1 ± 1.2
Acute phase reactants ESR (mm/hr) (normal value < 20 mm/h for men, < 30 mm/h for women) 30.3 ± 23.8
  CRP (mg/L) (normal value < 10 mg/L) 24.0 ± 30.8
Quality of life HUI2 score 0.59 ± 0.22
  HUI3 score 0.38 ± 0.29
DMARD therapy Receiving adalimumab + 0 DMARD, no. (%) 135 (15.4)
  Receiving adalimumab + 1 DMARD, no. (%) 371 (42.2)
  Receiving adalimumab + 2 DMARDs, no. (%) 284 (32.3)
  Receiving adalimumab + ≥ 3 DMARDs, no. (%) 89 (10.1)
  Receiving methotrexate, no (%) 549 (62.5)
  Receiving leflunomide, no. (%) 248 (28.2)
  Receiving sulfasalazine, no. (%) 104 (11.8)
  Receiving hydroxychloroquine, no. (%) 248 (28.2)
  Receiving prednisone, no. (%) 381 (43.3)
     Prednisone ≤ 5 mg, no. (%) 158 (18)
     Prednisone > 5 mg, no. (%) 223 (25.3)
  Patients that received prior BDMARD therapy no. (%) 242 (27.5)
  Patients that received etanercept no. (%) 131 (54.1)
  Patients that received infliximab no. (%) 65 (26.9)
  Patients that received other BDMARD no. (%) 46 (19)
  1. *Indicating a statistical difference (P < 0.05) between those that continued after the Week 12 visit and those that did not.
  2. a0 = no pain and 100 = severe pain.
  3. b0 = no disease activity and 100 = extreme disease activity.
  4. c0 = no difficulty and 3 = unable to perform activity.
  5. ACR: American College of Rheumatology; CRP: C-reactive protein; DAS28: 28-joint disease activity score; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; HUI: health utility index; RF: rheumatoid factor; VAS: visual analog scale.